RxDoctor Payments Data

Cameron Ramsay, MD

Cardiovascular Disease · Tualatin, ORNPI 1255455929

Payments from drug & device makers

$2,211in general payments, 2019–2025

Across 53 payments — averaging $41.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$280
  • Novartis$95
  • Amgen$84
  • Amarin Pharma, Inc.$83
  • Philips North America LLC$59
  • plus $270 from 10 others

What the payments were for

  • Travel & lodging$56926%
  • Food & beverage$1,62874%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,211 in reported general payments places this provider in the 60th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$86,022
Medicare patients
492
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban661$727,711
XareltoRivaroxaban71$97,702
EntrestoSacubitril/Valsartan66$91,151
Repatha SureclickEvolocumab50$47,322
FarxigaDapagliflozin Propanediol14$20,249
Praluent PenAlirocumab20$17,305
BrilintaTicagrelor25$15,798
JardianceEmpagliflozin15$14,987
Metoprolol Succinate773$11,584
Atorvastatin Calcium485$6,208
ClopidogrelClopidogrel Bisulfate328$4,590
Rosuvastatin Calcium192$3,201
Dofetilide12$2,676
Isosorbide Mononitrate ErIsosorbide Mononitrate109$2,244
Flecainide Acetate25$2,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$727,711661 claims
Johnson & JohnsonXarelto$38$97,70271 claims
NovartisEntresto$95$91,15166 claims
AstraZenecaFarxiga, Brilinta$32$36,04739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Tualatin

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →